State Street Corp Sellas Life Sciences Group, Inc. Transaction History
State Street Corp
- $2.41 Trillion
- Q3 2024
A detailed history of State Street Corp transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, State Street Corp holds 174,529 shares of SLS stock, worth $150,094. This represents 0.0% of its overall portfolio holdings.
Number of Shares
174,529
Previous 134,029
30.22%
Holding current value
$150,094
Previous $159,000
37.11%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$1.97 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$682,6980.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$520,4640.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$370,1160.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$265,2803.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $17.7M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...